Core Insights - Pyxis Oncology, Inc. has appointed Alex Kane as Senior Vice President of Investor Relations & Capital Markets, effective immediately [1] - Kane has 20 years of experience in investor relations and capital markets, particularly in the life sciences sector [2] - His previous roles include Vice President at Guggenheim Securities and senior positions at Praxis Precision Medicines and PTC Therapeutics, where he managed IPOs and investor engagement [3] Company Overview - Pyxis Oncology is a clinical-stage company focused on developing antibody-drug conjugate (ADC) therapeutics for challenging cancers [1] - The lead candidate, micvotabart pelidotin (MICVO), is currently in Phase 1 clinical studies targeting recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) [5] - The company has initiated a Phase 1/2 combination study of MICVO with Merck's KEYTRUDA® in patients with R/M HNSCC and other advanced solid tumors [5]